Zai Lab Announces Strategic Partnership, Exclusive Worldwide License Agreement With MediLink Therapeutics

Palo Alto – May 12, 2023 – Cooley advised Zai Lab, a research-based commercial-stage biopharmaceutical company, on its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as part of Zai Lab’s efforts to build its portfolio of potential first- and/or best-in-class antibody-drug conjugate (ADC) products. Partner Lila Hope led the Cooley team.

The agreement will grant Zai Lab full responsibility for all development and commercialization activities globally of MediLink’s YL212, a novel delta-like ligand 3 (DLL3) ADC program discovered by using MediLink’s proprietary TAMLIN platform, which leverages the tumor microenvironment to overcome challenges in current ADC drugs.

Based in China and the US, Zai Lab is focused on discovering, developing and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases and neuroscience.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.